Merck & Co., Inc. · MRK · Next earnings

Merck & Co., Inc. reports Tuesday, Feb 2, 2027

MRK reports before market open with consensus EPS at $1.77 and revenue at $16.32B. Last quarter: Merck Q3: Guidance Raised as Pipeline Progress Continues

Reports Before market open90 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.77 Calendar consensus
Consensus revenue $16.32B Calendar consensus
Report date Feb 2, 2027 Tuesday, date estimated
Session Before market open 90 days away

Where MRK left off: FY2026 Q3

Full report

Merck Q3: Guidance Raised as Pipeline Progress Continues

EPS surprise +19.1% Reported $2.49 vs $2.09
Revenue surprise +4.4% Reported $18.09B vs $17.33B
Stock move +3.8% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised FY2026 revenue guidance to $66.8-$67.3 billion and EPS guidance to $2.77-$2.82.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Generic competition may pressure BRIDON, Januvia and Adempas sales.
  • A $550 million timing benefit is expected to unwind in Q4 and 2027.
  • Policy and pricing pressure, vaccine hesitancy and KEYTRUDA QLEX litigation could weigh on results.

Questions analysts left open

  • Whether 2027 consensus estimates reflect the raised guidance.
  • Sustainability of earnings growth through KEYTRUDA loss-of-exclusivity and continued R&D investment.
  • The effect of KEYTRUDA QLEX litigation and timing benefits on future results.

Ask FN2 about MRK next report

Transcript, numbers and history already loaded
What should I watch for in MRK's next earnings report?How did MRK guide last quarter, and is consensus above or below that?Give me the bull and bear case going into MRK earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the MRK recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent MRK quarters

All MRK earnings
+3.8%FY2026 Q3+0.2%FY2026 Q2-1.6%FY2026 Q1+2.2%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.